Numbness and tingling in the hands can be unsettling, especially if it occurs frequently. It might feel like tingling, pins ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ARGX stock, giving a Buy rating yesterday.Stay Ahead of the ...

JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

To achieve the goals set out in its 'Vision 2030', argenx has set the following priorities for 2025: Expand the global VYVGART opportunity by reaching more patients broadly across MG, CIDP and ITP ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Argenx Se (ARGX – Research Report). The associated price ...

(“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it ...

The 2024 American College of Rheumatology (ACR) annual meeting spotlighted transformative advancements in cell therapies for autoimmune diseases, with chimeric antigen receptor (CAR)-T therapies ...

Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been given an average rating of “Moderate Buy” by the ten ...

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA PDUFA on track for April 2025 to support reachin ...